CD4 and inflammatory bowel disease: Other major therapies for IBD such as vedolizumab antibody blockade of the gut-homing integrin heterodimer α4β7 have been observed to impact innate immune cells more potently than their presumed CD4+ T-cell targets, in direct correlation with clinical efficacy [33].